These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21615212)

  • 1. From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.
    Zhang S; Farag SS
    Expert Opin Investig Drugs; 2011 Jul; 20(7):1015-28. PubMed ID: 21615212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
    Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
    Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ENMD-2076 for hematological malignancies.
    How J; Yee K
    Expert Opin Investig Drugs; 2012 May; 21(5):717-32. PubMed ID: 22397360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
    Altenburg JD; Farag SS
    Expert Opin Investig Drugs; 2015 Feb; 24(2):261-71. PubMed ID: 25494820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panobinostat for the treatment of multiple myeloma.
    Neri P; Bahlis NJ; Lonial S
    Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
    Matulonis UA; Lee J; Lasonde B; Tew WP; Yehwalashet A; Matei D; Behbakht K; Grothusen J; Fleming G; Lee NK; Arnott J; Bray MR; Fletcher G; Brokx RD; Castonguay V; Mackay H; Sidor CF; Oza AM
    Eur J Cancer; 2013 Jan; 49(1):121-31. PubMed ID: 22921155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
    Richardson PG; Mitsiades C; Ghobrial I; Anderson K
    Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
    Moreau P
    Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging pathways as individualized therapeutic target of multiple myeloma.
    Misso G; Zappavigna S; Castellano M; De Rosa G; Di Martino MT; Tagliaferri P; Tassone P; Caraglia M
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S95-109. PubMed ID: 23738692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.
    Yap TA; Olmos D; Molife LR; de Bono JS
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1293-304. PubMed ID: 21777167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
    de Queiroz Crusoe E; Maiso P; Fernandez-Lazaro D; San-Segundo L; Garayoa M; Garcia-Gomez A; Gutierrez NC; Delgado M; Colado E; Martin-Sanchez J; Lee FY; Ocio EM
    Ann Hematol; 2012 Feb; 91(2):257-69. PubMed ID: 21720745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical models of multiple myeloma: a critical appraisal.
    Schüler J; Ewerth D; Waldschmidt J; Wäsch R; Engelhardt M
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S111-23. PubMed ID: 23742200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib for previously untreated multiple myeloma.
    Delforge M
    Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
    Vallet S; Witzens-Harig M; Jaeger D; Podar K
    Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide therapy for myeloma.
    Schey S; Ramasamy K
    Expert Opin Investig Drugs; 2011 May; 20(5):691-700. PubMed ID: 21413906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.